Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease [Yahoo! F...
Janus Henderson Group plc Ordinary Shares (JHG)
Last janus henderson group plc ordinary shares earnings: 4/30 04:00 am
Check Earnings Report
US:NYSE Investor Relations:
snl.com/irw/corporateprofile/4147331
Company Research
Source: Yahoo! Finance
led by Omega Funds, with participation from additional new investors Wellington Management and Janus Henderson Investors Proceeds will fund ongoing clinical development of CLD-423, a bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways CAMBRIDGE, Mass., January 14, 2026 BUSINESS WIRE Caldera Therapeutics, Inc. (Caldera), a clinical stage biotechnology company developing the first-in-class bispecific antibody CLD-423 for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, today launched with $112.5 million total capital raised and announced that the first subjects have been dosed in the Phase 1 trial of its lead program, CLD-423. Caldera raised a $75 million Series A round from Atlas Venture, LAV and venBio, and most recently a $37.5 million Series A-1 round led by Omega Funds, with participation from new investors Wellington Management and Janus Henderson Investors. Caldera also announced that the first subjects have b
Show less
Read more
Impact Snapshot
Event Time:
JHG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JHG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JHG alerts
High impacting Janus Henderson Group plc Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JHG
News
- CNBC's UK Exchange newsletter: The battle for Britain's investment trusts [CNBC]CNBC
- Janus Henderson to Report Fourth Quarter and Full-Year 2025 Results [Yahoo! Finance]Yahoo! Finance
- Janus Henderson to Report Fourth Quarter and Full-Year 2025 ResultsBusiness Wire
- Andreessen Horowitz's shiny, new $15 billion reveals where the firm sees the biggest opportunities [Fortune]Fortune
- Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform [Yahoo! Finance]Yahoo! Finance
JHG
Earnings
- 10/30/25 - Beat
JHG
Sec Filings
- 12/31/25 - Form 3
- 12/29/25 - Form DEFA14A
- 12/23/25 - Form SCHEDULE
- JHG's page on the SEC website